Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Liminatus Pharma, Inc./ 10-Q

Quarterly Report · 10-Q

Liminatus Pharma, Inc.

LIMNNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:51 PM EDTCIK 1971387Accession 0001104659-26-097304
View company →Permanent SEC source ↗
Share

Company context

Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment.

Current securities

LIMNNASDAQ · EQUITY · CurrentLIMNWNASDAQ · WARRANT · Current

Recent company filings

  1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD DisclosureSep 29, 2026
  2. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 18, 2026
  3. Submission of Matters to a Vote of Security HoldersAug 4, 2026
  4. Other EventsJul 30, 2026
  5. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsJul 24, 2026

Registered securities in this filing

LIMINATUS PHARMA, INC. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
LIMN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Duration_1_1_2026_To_6_30_2026_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ohqKnz9dEUS0dmSQAg11ig

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants

Symbol
LIMNW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: Duration_1_1_2026_To_6_30_2026_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember_gVJhgF8sg0-d_EmP30Wt3g

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000110465926097304 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.